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Towards improvements in foot-and-mouth 
disease vaccine performance
Graham J. Belsham* 
Abstract 
Foot-and-mouth disease (FMD) remains one of the most economically important infectious diseases of production 
animals. Six (out of 7 that have been identified) different serotypes of the FMD virus continue to circulate in different 
parts of the world. Within each serotype there is also extensive diversity as the virus constantly changes. Vaccines 
need to be “matched” to the outbreak strain, not just to the serotype, to confer protection. Vaccination has been used 
successfully to assist in the eradication of the disease from Europe but is no longer employed there unless outbreaks 
occur. Thus the animal population in Europe, as in North America, is fully susceptible to the virus if it is accidentally (or 
deliberately) introduced. Almost 3 billion doses of the vaccine are made each year to control the disease elsewhere. 
Current vaccines are produced from chemically inactivated virus that has to be grown, on a large scale, under high 
containment conditions. The vaccine efficiently prevents disease but the duration of immunity is rather limited (about 
6 months) and vaccination does not provide sterile immunity or block the development of carriers. Furthermore, the 
vaccine is quite unstable and a cold chain needs to be maintained to preserve the efficacy of the vaccine. This can 
be a challenge in the parts of the world where the disease is endemic. There is a significant interest in developing 
improved vaccines and significant progress in this direction has been made using a variety of approaches. However, 
no alternative vaccines are yet available commercially. Improved disease control globally is clearly beneficial to all 
countries as it reduces the risk of virus incursions into disease free areas.
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Introduction
Foot-and-mouth disease (FMD) remains one of the 
most feared infectious animal diseases in countries 
with a highly developed livestock production industry 
as reviewed in [1–3]. The disease is caused by infection 
with FMD virus (FMDV), a member of the picornavirus 
family. The virus infects important domesticated pro-
duction animals including cattle, pigs, sheep, goats and 
buffalo plus about 70 species of other cloven-hoofed 
wildlife animals. The disease is diagnosed based on 
clinical signs, including high body temperature, exces-
sive salivation, formation of vesicles in and around the 
mouth and in the inter-digital spaces and on the coronary 
bands on the feet. Female animals may also have vesi-
cles on the teats. Similar clinical signs can also be caused 
by other viruses. Hence, in countries that are normally 
FMD free, it is essential that laboratory analysis is per-
formed on suspected cases (e.g. using real time quanti-
tative RT-PCR). Infected animals lose weight, are prone 
to secondary infections and the disease can cause long-
term loss of productivity, e.g. reduced milk yield. Within 
infected premises, a very high proportion of the animals 
often become infected since the virus spreads very eas-
ily between animals but there is only low level mortality, 
mainly  due to myocarditis in young animals. In cattle, 
buffalo and sheep (but not pigs), following the acute stage 
of infection, a high proportion of animals (e.g. about 
50% of cattle) may become persistently infected with 
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low levels of infectious virus present in the oropharynx. 
These animals are referred to as “carriers” [4–6]. This 
carrier-state is defined as the maintenance of the virus in 
the animal for more than 28 days post infection. Different 
species can carry the virus for months (sheep) or several 
years (cattle and buffalo). The epidemiological signifi-
cance of the carrier state is controversial; it has proved 
impossible to demonstrate, experimentally, transmission 
of the virus from carrier cattle to naïve cattle by natural, 
direct, contact. However, transmission from buffalo to 
cattle has been reported [7]. Recently, it has been dem-
onstrated that direct transfer of oropharyngeal fluid from 
carrier cattle into the oropharynx of naïve cattle resulted 
in very efficient infection [8]. Thus, it seems that carrier 
cattle do constitute a real risk for virus transmission even 
if that risk is quite low.
While some parts of the world are normally free 
from FMD, e.g. Europe and North America, it remains 
endemic in many countries, especially throughout much 
of Africa and in southern Asia. There has been a consid-
erable improvement in the disease status of South Amer-
ica. There were no reports of clinical disease between the 
outbreaks in 2013 (in Venezuela) and 2017 (in Colombia) 
[9], however extensive vaccination is still practiced in 
various countries in this region which may have masked 
virus circulation. FMD has been estimated to cause eco-
nomic losses of about 8–22 billion USD each year [10], 
in direct and indirect costs within endemic countries. 
The incursion of FMDV into normally disease free-coun-
tries can also have enormous economic consequences. 
Notably, the large outbreak of FMD that occurred in the 
U.K. in 2001 is estimated to have cost the country about 
10 billion USD [11]. This outbreak affected about 2000 
premises, lead to the destruction of over 6 million ani-
mals, and lasted for approximately 8 months. The disease 
also spread from the U.K. into Ireland, France and The 
Netherlands.
In the 1950s and 60s, very large numbers of FMD out-
breaks used to occur each year in Europe [12]. However, 
with well-organized veterinary services and the exten-
sive use of vaccination (in some countries), the situation 
improved dramatically and by the 1970s the number of 
outbreaks of the disease in Europe became very low. In 
consequence, vaccination against FMD was banned by 
the European Union (EU) in the early 1990s but emer-
gency vaccination, in the face of an outbreak, has been 
permitted [13]. One consequence of this approach is that 
the animal population in Europe is now fully susceptible 
to the disease, however this greatly facilitates trade in 
animals and animal products.
No vaccination was used in the U.K. to control the 
large outbreak of disease in 2001; however, in The Neth-
erlands, vaccination was employed as a control measure 
to restrict the spread of the disease but all the vaccinated 
animals were then destroyed [14].
There are seven different serotypes of FMDV known; 
these are termed O, A, C, SAT (Southern African Terri-
tories) 1, 2 and 3 plus Asia-1. There have been no reports, 
anywhere, of disease due to the serotype C FMDV since 
2004, thus this serotype may now be extinct outside of 
the laboratory [15]. There is little or no cross protection 
between the serotypes. Thus, animals that have been 
infected, or vaccinated, with one serotype remain highly 
susceptible to infection by other serotypes. Indeed, 
because of the heterogeneity of viruses even within a sin-
gle serotype, animals vaccinated with one specific strain 
of the virus may not be protected against infection by 
another virus of the same serotype. Thus, if vaccination is 
to be used, then there is a need to match vaccines against 
strains of the virus that are causing disease in the field, 
not only at the level of the serotype.
Serotype O FMDV is the most frequently reported 
form of the virus; it was reported, about 20  years ago, 
to be responsible for about 70% of the outbreaks glob-
ally [16] and this situation remains broadly unchanged 
[15]. As indicated above, there is significant diversity 
within serotypes, especially between viruses from dif-
ferent parts of the world. Indeed, with the exception of 
the Asia-1 serotype, each of the virus serotypes has been 
classified into different topotypes, based on nucleotide 
sequence analysis, with distinct geographical distribu-
tions [16, 17]. The SAT serotypes and Asia-1 viruses are 
quite geographically constrained (as their names suggest) 
but do occasionally move outside of their usual areas, 
indeed Asia-1 FMDV has reached Greece [18] and SAT 2 
FMDV has been present in Egypt in recent years [15]. In 
contrast, the O and A serotypes (and formerly the C sero-
type) have had wide geographical distributions.
Search strategy
This critical review is based mainly on published litera-
ture available in PubMed (http://www.ncbi.nlm.nih.gov/
pubme d) and builds upon extensive experience of this 
topic.
Current FMDV vaccines
Globally, about 2.5 billion doses of FMD vaccine are 
used annually, mainly in China and South America 
[10]. Currently, FMD vaccines are normally pro-
duced, under high containment conditions, by grow-
ing the infectious virus within baby hamster kidney 
(BHK) cells in suspension culture. The virus particles 
are chemically inactivated using binary ethyleneimine 
(BEI), which modifies the viral RNA, then puri-
fied to remove non-structural viral proteins. Prior to 
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administration, the vaccine is mixed with an adjuvant 
(oil or in aqueous form with aluminium hydroxide and 
saponin).
Infectious FMDV particles are roughly spheri-
cal (about 25–30  nm in diameter) and have a protein 
shell, which contains 60 copies of each of the 4 differ-
ent structural proteins VP1–VP4, that encloses a single 
copy of the positive sense RNA genome (Fig.  1). The 
FMDV RNA genome includes one, large, open reading 
frame and acts like a mRNA encoding a single poly-
protein (Fig.  1). However, the intact polyprotein is 
never observed since during, and after, translation, the 
polypeptide chain is cleaved, mainly by virus-encoded 
proteases (L and 3C), to produce a variety of primary 
precursors (P1-2A, P2 and P3), which are further pro-
cessed to make a collection of 15 mature virus proteins 
(see below). The four structural proteins (VP1–VP4) 
are generated from the P1-2A precursor while the 
non-structural proteins (NSPs), which are mainly 
involved in protein processing, RNA replication and 
anti-host defense mechanisms, are derived from the P2 
and P3 precursors.
Virus particle assembly
The FMDV particles are assembled through a series of 
steps. The various intermediates are identified from their 
sedimentation characteristics (S value) during sucrose 
gradient centrifugation. This type of analysis may put 
constraints on what can be detected since the interme-
diates have to be stable for the duration of the analytical 
procedure. The capsid precursor P1-2A (Fig. 2) is modi-
fied at its N-terminus by the addition of a myristate (C14) 
group through the action of a cellular myristoylation sys-
tem [19, 20]. It is also cleaved by the 3C protease  (3Cpro) 
to produce VP0, VP3, VP1 plus the 2A peptide, the latter 
is not usually incorporated into the virus but it can be, 
as VP1-2A, if the cleavage junction is modified [21]. The 
capsid proteins remain associated with each other within 
a protomer (5S) and 5 protomers assemble together to 
form a pentamer (12S). Subsequently, twelve pentamers 
assemble, with the viral genome, to form the intact virus 
particle (146S). During this final assembly step, the VP0 
is cleaved to VP4 plus VP2 by an unknown mechanism. 
Assembly of pentamers into non-infectious empty capsid 
particles (70S), lacking the RNA genome, can also occur. 
At least with FMDV, the cleavage of VP0 seems to be 
Fig. 1 Production and processing of FMDV proteins. The FMDV RNA (top) encodes a large polyprotein that is processed, during and after 
translation, to a collection of precursors (P1-2A, P2 and P3) and mature products largely through the action of the 3C protease. Many other 
processing intermediates are made but are not shown. The cleavage of the myristoylated VP0 to VP4 and VP2 occurs during particle assembly. The 
myristoylation of the N-terminal glycine of the capsid precursor P1-2A is achieved by a host cell system. The two forms of the Leader protease (Lab 
and Lb) cleave themselves from the capsid precursor. The 5′ UTR includes extensive secondary structure, one region is the internal ribosome entry 
site (IRES) required for initiation of protein synthesis on the viral RNA
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dependent on the particle assembly process rather than 
the presence of viral RNA [22, 23], thus assembled empty 
capsid particles have been found to contain VP2. The 
production of empty capsid particles seems to vary in 
efficiency between virus strains; serotype A empty capsid 
particles are readily formed within FMDV-infected cells 
[24] but are less abundant with most strains of serotype 
O virus. This may have consequences for the efficiency 
with which empty capsid particles, of different strains/
serotypes, can be generated using recombinant protein 
expression systems [25].
The intact virus particles (or empty capsid particles) 
are much more immunogenic than individual virus com-
ponents or even partially assembled virus particles (e.g. 
pentamers) or their breakdown products [26]. Thus, it is 
important to ensure that vaccines contain a high level of 
intact particles when produced and that they are stored 
under conditions that preserve this (including use of a 
cold chain during vaccination campaigns). Systems to 
detect and quantify the presence of intact particles (of 
certain serotypes) have been developed [27, 28].
Limitations of current FMD vaccines
As indicated above, the vaccine has been proven to be 
very effective in helping to control the disease in Europe, 
in conjunction with other control measures including 
animal movement controls, but the current FMD vac-
cines are far from perfect. Vaccination prevents the 
appearance of disease but limited virus replication, espe-
cially in the oropharynx, can still occur in these animals 
and this can be sufficient to allow those vaccinated ani-
mals, which do get infected, to become carriers and thus 
harbor the infectious virus for a long period of time.
If the virus particles are purified away from the non-
structural proteins (NSPs) during manufacture, then it is 
possible to distinguish, by serology, between animals that 
have been vaccinated against FMD but not infected and 
those that have been infected with the virus (the DIVA 
concept). Both the virus infection and the inactivated 
vaccine induce the production of antibodies against the 
capsid proteins. In contrast, antibodies against the NSPs 
should only be generated by infection (although mul-
tiple vaccinations with purified vaccines may still elicit 
an anti-NSP response). A variety of assays are available 
to detect antibodies against the NSPs [29]. However, if 
a vaccinated animal becomes infected (albeit without 
disease) then the level of virus replication in these car-
rier animals may be insufficient to generate an immune 
response to the NSPs even though the infectious virus is 
still carried by the animals [29, 30].
Some of the limitations of the current FMD vaccines 
are discussed further below. Some of these limitations 
reflect the nature of the vaccine while others reflect the 
biology of the virus, in particular its rapid evolution 
including incremental genetic drift and more radical 
recombination events.
FMDV biology
The FMDV genomic RNA is positive sense and, when 
introduced into the cytoplasm of cells, is sufficient to ini-
tiate infection [31, 32]. The RNA sequence contains a sin-
gle, large, open reading frame (ca. 7000 nucleotides (nt)) 
encoding a polyprotein that is flanked by a long (ca. 1300 
nt) 5′-untranslated region (UTR) and a much shorter 
3′-UTR (ca. 90 nt) followed by a poly(A) tail (Fig. 1). Ini-
tially the genomic RNA has to function like a mRNA; 
it encodes a polyprotein of about 2300 amino acids. 
However, the complete polyprotein is never made as it 
is cleaved during, and after, synthesis into a variety of 
precursors that are further processed to make 15 differ-
ent mature proteins (Lab, Lb, VP4, VP2, VP3, VP1, 2A, 
2B, 2C, 3A, 3B1, 3B2, 3B3, 3C and 3D) (see Fig. 1). These 
include the 4 distinct structural proteins (VP1, VP2, VP3 
and VP4) that form the virus capsid  (Fig.  2). This pro-
tein shell (with 60 copies of each capsid protein per par-
ticle) protects the viral RNA when the virus is outside 
of a cell and also facilitates delivery of the viral RNA to 
the cytoplasm of a new cell so that a new round of infec-
tion can occur. The capsids bind to cell surface integrin 
receptors [33] and, following virus entry, the mild acidi-
fication that occurs within endosomes [34] is sufficient 
to breakdown the acid-labile virus capsid and permit 
the release of the viral RNA so that translation can com-
mence. The eleven non-structural proteins, include two 
different forms of the Leader proteinase (termed Lab and 
Lb), resulting from initiation of translation at two differ-
ent AUG codons [35] and three non-identical forms of 3B 
(termed 3B1, 3B2 and 3B3). These 3 short peptides are 
also known as VPg (Virus Protein genome linked) as they 
are covalently linked to the 5′-terminus of all the newly 
synthesized viral RNA (Fig. 1). Each VPg can act as the 
substrate for uridylylation to form VPgpUpU [36], which 
then acts as the primer for RNA synthesis. The 3C pro-
tease  (3Cpro) is responsible for most of the proteolytic 
processing events within the FMDV polyprotein while 
the 3D protein is the RNA dependent RNA polymerase, 
termed  3Dpol. The properties and functions of the differ-
ent virus encoded proteins have been reviewed in detail 
separately [37, 38] and will not be repeated here.
Viral RNA replication is error prone
In addition to acting as a mRNA, the FMDV genome 
also acts as the template for RNA replication. Thus, for at 
least one molecule within each infected cell, translation 
of the input viral RNA has to cease to allow the synthesis 
of a negative sense RNA. Note, during protein synthesis, 
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the ribosomes move along the RNA in a 5′ to 3′ direc-
tion while, for RNA replication, the RNA polymerase 
begins synthesis of the negative strand at the 3′-terminus 
of the RNA; these processes cannot occur simultaneously 
on the same molecule. The newly synthesized negative 
strand is then used as the template for the production of, 
many more, positive-sense RNA copies that can be used 
for translation (for the production of viral proteins), or as 
a template for further negative sense RNA production or 
packaged into new virus particles (Fig. 2).
The replication of viral RNA occurs in structures, 
derived from intracellular membranes [39], termed repli-
cation complexes or replication organelles which contain 
a number of host and viral proteins (including 2C and 
 3Dpol) that are required for the process [40]. The replica-
tion of the viral RNA is highly error prone, i.e. incorrect 
nt are incorporated into the RNA copies. Assessments 
of the error rate of the RNA polymerase suggest that, on 
average, about one error is made for every 10,000 nt that 
are synthesized [41]. This means that it can be expected 
that nearly every FMDV genome has at least one error 
since about 17,000 nt have to be copied to make one new 
genomic RNA molecule (after copying both a positive 
and a negative strand). There is no known proof reading 
mechanism in picornaviruses; thus, the total viral RNA 
population represents a pool of closely related sequences; 
this pool is known as a quasi-species [42]. Modifica-
tions to the fidelity (that either increase or decrease the 
error rate) of the  3Dpol from picornaviruses reduce the 
“fitness” of the virus [43]. Thus, it appears that for these 
viruses, there is a balance between the need to maintain 
a fully functional RNA sequence and the requirement to 
be able to adapt rapidly to new conditions. As a result of 
this continuous generation of errors, the virus popula-
tion is always evolving. However, it should be noted that 
the “consensus” sequence (i.e. corresponding to the pre-
dominant nt present at each position in the genome) of 
the virus population will only change relatively slowly 
(compared to the error rate) when some of the errors 
become fixed (i.e. they become predominant), presum-
ably because they confer some selective advantage. The 
consensus sequence of the FMDV population changes 
at 0.5–1.0% of the genome per year [44]. This repre-
sents about 40–80 nt per year or around 1–2 nt changes 
per week. These differences in sequence can potentially 
modify the biology of the virus, (e.g. in its antigenicity or 
speed of replication) but can also be useful for tracing the 
spread of viruses during disease outbreaks [44, 45].
It can be expected that RNA polymerase errors will 
occur throughout the entire viral genome and evidence 
derived from the analysis of different virus isolates 
obtained from the outbreak in the U.K. in 2001, starting 
from a single source and spreading within unvaccinated 
animals, suggests that this is indeed the case [44]. From 
a collection of nearly 200 different nt substitutions iden-
tified within 23 different full-length virus sequences, 
some 28 changes were within the non-coding regions 
(i.e. about 14%, which is close to the proportion of the 
genome that these non-coding regions constitute within 
the genome). Within the coding region for the whole 
polyprotein, a major proportion of the changes observed 
were synonymous and only 40 (20%) of the changes mod-
ified the encoded protein sequence. Thus, it seems clear 
that selection to retain the amino acid sequence is high. 
Amino acid changes that modify the function of the pro-
tein are usually going to be deleterious and thus will not 
be maintained. However, some regions of the genome 
are much more tolerant to change than others. Clearly, 
within a vaccinated population there can be selection 
pressure for variants that have modified antigenicity.
FMDV sequence diversity
From comparing over 100 strains of FMDV, including 
representatives of all 7 serotypes, Carrillo et al. [46] found 
that within the 5′-UTR, the average nt identity between 
all serotypes is over 80% and for the entire polyprotein 
coding region (ca. 7000 nt) the level of sequence identity 
between any two virus isolates was at least 73%. However, 
the VP1 coding region (about 639 nt) is substantially 
more variable between strains than most of the polypro-
tein coding sequence and shows only about 50–70% nt 
identity between all serotypes [47]. The VP1 itself has the 
lowest proportion (24%) of invariant amino acids among 
the different products derived from the polyprotein [46]. 
Presumably this reflects the ability of certain residues 
to accept change (e.g. in loop regions connecting struc-
tural elements within the surface exposed capsid proteins 
VP1, VP2 and VP3) and selection pressure resulting from 
immune responses to these exposed features of the virus 
particle. The capsid protein VP4, which is entirely inter-
nal within the intact particle, is much less variable (81% 
invariant residues, [46]).
Some surface exposed parts of the capsid proteins 
(including the antigenic sites, see below) are clearly able 
to change extensively. However, even within the VP1 
capsid protein, there are highly conserved motifs, e.g. 
the RGD (Arg-Gly-Asp) motif. This is critical for inter-
action with the cellular integrin receptors and therefore 
required for virus attachment and entry into cells [33]. 
Similarly, a very highly conserved YCPRP (Tyr-Cys-Pro-
Arg-Pro) motif near the C-terminus of FMDV VP1 was 
apparent from the alignments performed by Carrillo 
et al. [46] but its significance has only recently been rec-
ognized [48, 49]. This motif is required for processing of 
the capsid precursor P1-2A by the  3Cpro and is also highly 
conserved between different picornavirus genera (e.g. 
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WCPRP in enteroviruses and FCPRP in cardioviruses; 
note, W (Trp) and F (Phe) are aromatic amino acids like 
Y (Tyr)). No doubt, errors in the nt sequences encoding 
these conserved amino acids do occur but presumably 
the resultant viruses (if viable at all) are not efficiently 
propagated and hence such variants are not maintained 
within the virus population.
RNA recombination
In addition to the gradual accumulation of nt changes 
described above, a more dramatic form of genome evo-
lution, involving RNA recombination, can also occur 
within picornavirus genomes. During the process of 
picornavirus RNA replication, it is possible for the RNA 
polymerase  (3Dpol) to switch from copying one positive 
strand template to another [50], by a so-called “copy-
choice” mechanism. This process can result in the forma-
tion of “chimeric” genomes, e.g. with the capsid coding 
sequences derived from one parental virus and the rest 
of the genome derived from a different strain of the virus 
[51, 52]. Thus, recombination can change the serotype 
of the virus. The switching of templates during RNA 
replication may occur very frequently during RNA rep-
lication but if all the genomes within a single cell are all 
very closely related then this will not have any significant 
effect on the outcome of the RNA replication process and 
will be hard to detect. However, if a cell is co-infected 
with two genetically distinguishable genomes then a 
novel chimeric genome can be produced by the recombi-
nation that may, or may not, be viable. If it is viable, then 
it can have different properties from each of the parental 
virus strains and, under appropriate conditions, may rep-
licate preferentially. Clearly, the production and detec-
tion of a novel recombinant virus in the field requires 
that an animal is co-infected with distinguishable strains 
of the virus. In some parts of the world, multiple sero-
types of the virus frequently co-circulate and evidence for 
inter-serotypic recombination in FMDV in the field has 
been described [51, 53, 54]. Evidence for recombination 
between different lineages of the same serotype has also 
been reported [55]. The identification of recombination is 
facilitated if (near) full-length genome sequences are gen-
erated so that the genetic relationships between different 
parts of the genome to other viruses can be established 
[54].
How does recombination occur?
As indicated above, detecting recombination requires 
that an animal is co-infected with two distinct strains of 
FMDV. Indeed, the same cells within the host need to be 
Fig. 2 The assembly of FMDV particles. The myristoylated capsid precursor protein (P1-2A) is cleaved by the 3C protease to form protomers 
(5S) consisting of VP0, VP3 and VP1. Five of these protomers assemble into pentamers (12S) and 12 of these combine to form the near spherical 
capsid particles containing 60 copies of each of the viral capsid proteins. When RNA is packaged, then infectious particles are formed (146S) but 
non-infectious empty capsid particles (70S), without any viral RNA, can also be made (not shown). The cleavage of VP0 to VP4 and VP2 (see Fig. 1) 
accompanies the process of particle assembly and, at least for FMDV, does not require the presence of viral RNA
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infected at the same time by each virus so that the viral 
RNA polymerase can switch between the two differ-
ent FMDV RNA templates. When an animal is infected 
with FMDV, there is usually a fairly short, acute phase of 
infection [1, 56]. A high level of viremia is apparent for a 
few days and vesicular lesions, containing high levels of 
virus, are observed. The infection subsides as a protec-
tive immune response is generated and the vesicles heal. 
However, as indicated above, many infected animals (ca. 
50% of cattle) do not completely clear the infection and 
maintain a low level of infectious virus within the oro-
pharynx for months or even years. It should be noted that 
pigs do not become carriers [57]. It is not yet established 
whether recombination between FMDVs occurs when 
the parental viruses are each causing an acute infection 
within an animal simultaneously or if the re-infection of a 
“carrier” animal with a different virus is capable of allow-
ing co-infection of cells with the two different strains of 
virus. The extremely high level of virus present within 
an acutely infected animal potentially makes it easier 
for individual cells within the host to be co-infected but, 
clearly, this imposes a fairly narrow time window for the 
co-infection of the cells to occur. However, re-infection 
of a “carrier” animal with a different strain of virus could 
occur at a time interval of weeks, months or even years 
after the primary infection. If carrier status is the key to 
recombination, under field conditions, then it should not 
happen in pigs. In general, it is not known in which spe-
cies any recombinant event has occurred but a recent 
study provided evidence for recombination between dif-
ferent variants of SAT 1 FMDV within experimentally 
infected African buffalo (Syncerus caffer) [58]. Thus, it 
should be possible to design experiments to determine if 
recombination between FMDVs can occur in pigs.
Antigenic diversity of FMDV and vaccine selection
The existence of 7 serotypes of FMDV clearly indicates 
that the genetic diversity displayed by the virus results in 
antigenic diversity as well. The antigenic properties of the 
virus are dependent on the surface exposed residues of 
VP1, VP2 and VP3 (note VP4 is entirely internal within 
the virus particle, [59]).
Antigenic matching between viruses is important for 
the selection of the most appropriate vaccine to protect 
against a strain of FMDV causing disease. In principle, 
this could be performed by conducting a vaccination trial 
within natural host animals with potential vaccines and 
then challenging the animals with the outbreak strain. 
This would be very time consuming and expensive. In 
practice, in  vitro neutralization assays are commonly 
used to determine whether antisera generated by particu-
lar vaccines are able to efficiently neutralize the outbreak 
strain. Unfortunately, such assays can be rather poorly 
reproducible [60].
Vaccine potency testing
The usual potency testing of FMDV vaccines involves 
the inoculation of a necessarily small number of animals 
with different doses of the vaccine and then challenge, 
by needle inoculation, at 21 or 28 days post vaccination, 
with an appropriate (normally homologous) virus strain 
[61]. While this test has some useful features, in terms of 
standardization, it also has certain limitations. For exam-
ple, the test does not give information about the ability 
of the vaccine to protect against non-homologous virus 
strains or to protect against a more usual form of virus 
challenge, i.e. by exposure to an infected animal, and 
only relates to a single time point post-vaccination with 
limited precision due to the small groups of animals. A 
detailed and comprehensive review of the issues relating 
to evaluating, in the laboratory, the protection conferred 
by specific FMD vaccines has been published by Paton 
et al. [60]. Some field studies to examine the effectiveness 
of FMD vaccines against a specific virus threat have also 
been reported [62]. Furthermore, a review considering 
the design of studies to assess the efficacy of vaccines in 
the field has been published recently [63].
Monoclonal antibodies (Mabs) raised against FMDV 
can be used as standardized reagents to assess the anti-
genicity of different viruses. Such Mabs that neutralize 
virus infectivity have been used to select for neutraliza-
tion resistant mutants of FMDV using a range of different 
serotypes of the virus. By sequencing the selected, neu-
tralization resistant, viruses, it is possible to identify key 
surface exposed residues in FMDVs that are important 
for the antigenicity of the virus. Using this approach, mul-
tiple, independent antigenic sites have been identified. 
In general, these antigenic sites are located on surface 
exposed loops and each of the surface exposed capsid 
proteins make some contribution towards them [64–71]. 
Interestingly, sequential selection of a serotype O virus 
that was resistant to neutralization at each of 4 separate 
antigenic sites still resulted in a virus that was efficiently 
neutralized by a serotype O-specific polyclonal antiserum 
[72]. Thus, the relationship between the antigenic sites, 
defined by selection with murine Mabs, and the epitopes 
recognized by sera from natural host animals is not sim-
ple. It should be noted, however, that the antigenic sites 
identified using Mabs do correspond to regions of high 
sequence variability within field viruses suggesting these 
regions have changed due to antigenic pressure. These 
studies do not, however, necessarily, reveal all residues 
bound by the Mab. For example, if a Mab binds to a 
region of the virus that has to be maintained for virus via-
bility (e.g. to bind to the integrin receptor) then clearly, 
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the Mab-resistant mutants selected will not be modi-
fied at that residue. Indeed, an analysis of the interaction 
between a particular Mab (D9) with the intact serotype O 
virus, using cryo-electron microscopy, revealed interac-
tion of the Mab with residue D147 within VP1 (part of 
the RGDL motif required for integrin binding) that had 
not been identified previously from sequencing of neu-
tralization resistant mutants [73]. However, substitution 
of the adjacent residue L148 in VP1 had been shown to 
result in strong resistance to neutralization by the Mab 
D9 [64, 66], thus it is not surprising that residue D147 
also interacts with the antibody.
In principle, it is possible to assess how an outbreak 
strain of FMDV corresponds to known vaccine strains 
in these key antigenic regions of the virus capsid either 
through measuring reactivity with mapped Mabs or from 
sequence determination [74–76]. However, the ability 
of a vaccine to efficiently confer protection against virus 
challenge in the field undoubtedly depends on many fac-
tors, in addition to the actual “match” between the out-
break virus and the vaccine. An analysis of the ability of 
a range of different serotype O vaccine strains to combat 
multiple serotype O viruses circulating in southern Asia 
has been published [77]. It is apparent that the over-
all ability of a vaccine to induce neutralizing antibodies 
(as measured by in vitro virus neutralization tests) must 
be important but within the host, it is possible for non-
neutralizing antibodies to reduce the level of circulat-
ing virus as well. The strength of the immune response 
to the vaccine will also depend on the amount of antigen 
that is in the vaccine and its integrity as intact particles. 
High potency vaccines can generate protective immu-
nity within a few days [78] and this immunity can last 
for at least 6  months from a single dose [79]. However, 
the duration of immunity generated by the current inac-
tivated vaccines (using a standard dose) is often rather 
limited. In endemic regions, it is frequently necessary to 
re-vaccinate animals at least two times per year [80] to 
maintain protection. Thus, the timing between vaccina-
tion and the exposure to virus challenge and also, per-
haps, the actual level of virus encountered in the field can 
be important.
It is worth noting that some FMD vaccines, e.g. the 
widely used O1 Manisa vaccine, are based on viruses 
that circulated a long time ago (O1 Manisa was isolated 
in 1969). However, despite the genetic diversity of the 
virus, high potency vaccines based on this strain are still 
able to provide protection against heterologous serotype 
O strains [81, 82]. Similarly, intra-serotypic protection 
against very diverse serotype A strains has been demon-
strated with high payload serotype A vaccines despite low 
levels of antigenic “match” [83].
Prospects for improved FMD vaccines
A variety of reviews have described the need for 
improved FMD vaccines [80, 84, 85] and the current sta-
tus of developments towards improved FMD vaccines 
[38, 86]. For a detailed description of the major current 
strategies for the development of new FMDV vaccines 
the reader is referred to these reviews. In brief, there are 
just a few main approaches that have continued attention. 
These are outlined in Fig. 3. Essentially each approach is 
aimed at producing virus-like particles that display the 
spectrum of antigenic sites that are present on the virus 
particle itself. Attempts to use individual capsid proteins 
or synthetic peptides as candidate vaccines have proven 
unsuccessful. The main focus is now on three types of 
system which are:
(a) The production of non-infectious empty capsid par-
ticles, essentially by the co-expression of the myris-
toylated capsid precursor P1-2A with the  3Cpro 
(Fig. 3a) [25, 87, 88].
 The virus vector systems (e.g. vaccinia virus or 
baculovirus) used to express empty capsid parti-
cles in cell culture do not rely on the ability of the 
FMDV particles to be able to initiate an infection 
and this allows modification of the capsid proteins 
to enhance the stability of the assembled particles 
[88, 89]. These systems also offer the potential for 
production of FMDV antigens without the need for 
high containment facilities. However, it seems likely 
that vaccines based on these products will continue 
to suffer from some of the same issues as the cur-
rent inactivated vaccines, e.g. short duration of 
immunity, lack of sterile protection with the possi-
bility of carrier animal production.
(b) Use of a replication defective viral vectors to 
express FMDV empty capsids (Fig. 3b) [90, 91].
 This approach differs from the non-infectious sys-
tems described above in that the defective virus 
vectors are able to infect cells within the host 
(but do not spread) and thus the FMDV products 
are produced within the cells of the recipient ani-
mals. This can allow a broader range of immune 
responses to be mounted by the host than are gen-
erated by an extracellular protein antigen. The sys-
tem based on the human adenovirus vector (Ad5) 
has received “conditional licensing” in the USA that, 
for the first time, allows production of FMDV vac-
cine on the US mainland. Currently, high doses of 
this vaccine are required to achieve protection and, 
perhaps surprisingly, the duration of protective 
immunity also declines after about 6  months [92] 
while the continued presence of anti-adenovirus 
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antibodies may preclude re-vaccination. This may 
limit the utility of these vaccines to emergency use 
to combat an outbreak in countries that are usually 
disease free. The alphavirus system, as used by Gull-
berg et al. [91], is rather complex to produce but has 
the advantage that the alphavirus vector, based on 
an RNA genome [93], replicates solely within the 
cytoplasm of cells, as does FMDV, and thus issues 
related to RNA modifications within the nucleus 
(e.g. splicing, as occurs with the Ad5 vectors) are 
not relevant.
(c) Development of modified FMDV strains that are 
fully attenuated in animals but can be grown effi-
ciently in cell culture (e.g. based on the forms of 
the virus that lack the coding region for Lb (Fig. 3c) 
[94].
 It is possible to precisely delete the Lb coding region 
from FMDV virus without loss of viability within 
BHK cells (e.g. [94, 95]). However, these mutant 
viruses are highly attenuated in animals and cannot 
easily revert to virulence. Thus, these attenuated 
FMD viruses represent a significantly safer source 
of FMDV antigen than current vaccine strains. In 
the unlikely event that escape of the virus from a 
production facility occurred, the virus would not 
be able to infect animals and then be transmitted 
by them. It seems likely that such products could 
be produced at lower levels of containment than are 
required for conventional FMDV vaccine but they 
will have similar properties and limitations as the 
conventional vaccine. Presumably, the attenuated 
particles would be chemically inactivated and puri-
a
b
c
Fig. 3 Alternative strategies to produce novel, safe, FMDV vaccines. a The production of 70S empty capsid particles by the co-expression of the 
FMDV P1-2A capsid precursor plus the  3Cpro has been achieved using baculovirus and vaccinia virus expression systems. The purified non-infectious 
particles can be used as a vaccine. b Defective viral vectors (e.g. human adenovirus Ad5 or Semliki Forest virus vectors) have been used to express 
the P1-2A plus  3Cpro within mammalian cells. These viral vector vaccines can infect the host’s cells but cannot spread within the host. The FMDV 
P1-2A + 3C proteins are expressed from the vector within the infected cells and thus produce intracellular empty capsid particles. c Defective 
FMDVs, lacking the Lb coding sequence (c.f. Fig. 1), have been shown to be attenuated in animals and thus can be used to grow FMDV antigen in 
BHK cells more safely, as infectious virus. It is still expected that the virus will be inactivated prior to use as vaccine, as for current vaccines
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fied prior to use, as with conventional FMD vaccine 
viruses.
Conclusions
Improved knowledge of FMDV biology has allowed 
the design of novel candidate vaccines using a variety 
of approaches. Several, distinct systems are still being 
actively studied but, currently, only the conventional, 
inactivated FMDV vaccines, essentially developed in 
the 1960′s, are available for widespread use to combat 
the disease. The apparent disappearance of serotype 
C FMDV globally and the usual freedom from disease 
in Europe together with the much improved FMD 
situation in South America demonstrate that existing 
disease control measures, including use of current vac-
cines, can be effective. In endemic settings, it is clearly 
important to ensure that confidence in existing vac-
cines is maintained, or strengthened. Tests to ascertain 
vaccine quality, both during production and after stor-
age/transportation should be performed. Poor vaccine 
effectiveness may not only result from a poor match 
between the vaccine and the circulating virus.
There remains significant interest in developing bet-
ter FMD vaccines as the disease is still a major prob-
lem in many countries and represents a huge barrier to 
trade in animals and their products for these countries. 
Improved disease control globally is clearly beneficial 
to all countries as it reduces the risk of virus incursions 
into disease-free areas that can have enormous finan-
cial consequences.
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